Status:
RECRUITING
Membrane Target Detection for Leukemia Treatment
Lead Sponsor:
University of Missouri-Columbia
Conditions:
Hematological Malignancy
Eligibility:
All Genders
18+ years
Brief Summary
Acute myeloid leukemia (AML) accounts for more than 40% of leukemia mortality in the United States. Each year around ten thousand people die from the disease, most within a few years of diagnosis. Des...
Detailed Description
Specific targets and novel strategies to eliminate AML stem cells are required for AML treatment. Collecting specimens from the blood and bone marrow will increase understanding of the effect of DPP4 ...
Eligibility Criteria
Inclusion
- All hematological malignancy patients.
- Must be 18 years old.
Exclusion
- Participants with impaired decision-making capacities;
- Pregnant women or fetuses;
- Children (under 18 in Missouri, also dependent on State law);
- Non-viable neonates or neonates of uncertain viability (neonates=newborns);
- Non-English-speaking subjects;
- Prisoners.
Key Trial Info
Start Date :
March 20 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 20 2027
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04841447
Start Date
March 20 2020
End Date
March 20 2027
Last Update
December 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Missouri
Columbia, Missouri, United States, 65212